|
CA2381770C
(en)
*
|
1999-08-24 |
2007-08-07 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP2338515A3
(en)
|
2000-02-10 |
2011-11-16 |
Abbott Laboratories |
Antibodies that bind human interleukin-18 and methods of making and using
|
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
EE05715B1
(et)
|
2001-01-05 |
2014-06-16 |
Pfizer Inc. |
Antikehad insuliinitaolise kasvufaktori I retseptorile
|
|
HUP0501113A3
(en)
|
2001-04-26 |
2007-12-28 |
Biogen Idec Inc |
Cripto blocking antibodies and uses thereof
|
|
JP2005519580A
(ja)
|
2001-05-16 |
2005-07-07 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
非ヒト動物由来のヒト抗肺炎球菌抗体
|
|
IL149701A0
(en)
*
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
|
TR201900581T4
(tr)
*
|
2001-06-26 |
2019-02-21 |
Amgen Fremont Inc |
Opgl ye karşı antikorlar.
|
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
DE60328195D1
(de)
|
2002-03-29 |
2009-08-13 |
Schering Corp |
Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
|
|
AU2003234736B2
(en)
|
2002-04-12 |
2008-09-25 |
E. R. Squibb & Sons, L.L.C. |
Methods of treatment using CTLA-4 antibodies
|
|
JP2006500931A
(ja)
*
|
2002-09-30 |
2006-01-12 |
ファイザー・プロダクツ・インク |
高レベルのヒト配列抗体を産生するハイブリドーマ
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
US7273610B2
(en)
|
2003-08-14 |
2007-09-25 |
Dyax Corp. |
Endotheliase-2 ligands
|
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
|
MX350383B
(es)
|
2004-01-09 |
2017-09-04 |
Pfizer |
Anticuerpos contra madcam.
|
|
JP2007530526A
(ja)
*
|
2004-03-26 |
2007-11-01 |
ファイザー・プロダクツ・インク |
抗ｃｔｌａ−４抗体の使用
|
|
US7494779B2
(en)
|
2004-06-14 |
2009-02-24 |
Li-Te Chin |
Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
|
|
DK2287195T3
(da)
|
2004-07-01 |
2019-08-19 |
Innate Pharma |
Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
|
|
MX2007000610A
(es)
|
2004-07-16 |
2007-03-07 |
Pfizer Prod Inc |
Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
|
|
EP2899277A1
(en)
*
|
2004-11-26 |
2015-07-29 |
Pieris AG |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
CA2600608A1
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising human igg2 antibody and chelating agent
|
|
WO2006101691A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
|
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
|
US7812135B2
(en)
|
2005-03-25 |
2010-10-12 |
Tolerrx, Inc. |
GITR-binding antibodies
|
|
NL1031674C2
(nl)
|
2005-04-25 |
2007-04-26 |
Pfizer |
Antilichamen tegen myostatine.
|
|
EP2444421A1
(en)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin antibodies
|
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質ｖｉモノクローナル抗体
|
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
|
NZ563193A
(en)
|
2005-05-09 |
2010-05-28 |
Ono Pharmaceutical Co |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101510065B1
(ko)
|
2005-06-08 |
2015-04-07 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
|
CN101268101A
(zh)
*
|
2005-07-07 |
2008-09-17 |
科利制药集团公司 |
用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
|
|
CN100443503C
(zh)
*
|
2005-07-18 |
2008-12-17 |
四川大学华西医院 |
人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
|
|
CN101370525B
(zh)
|
2005-08-19 |
2013-09-18 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
GEP20125398B
(en)
|
2005-09-07 |
2012-02-27 |
Amjen Freemont Ink |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
CA2624562A1
(en)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
|
|
US7611702B2
(en)
|
2005-11-08 |
2009-11-03 |
Medarex, Inc. |
TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
|
|
PL1976877T5
(pl)
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
|
CN117903302A
(zh)
|
2005-11-30 |
2024-04-19 |
Abbvie 公司 |
抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
|
|
CA2630157C
(en)
|
2005-12-07 |
2018-01-09 |
Medarex, Inc. |
Ctla-4 antibody dosage escalation regimens
|
|
EP2889309B1
(en)
|
2006-03-03 |
2017-12-27 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of pd-1 or pd-l1
|
|
AU2007241023B2
(en)
|
2006-03-30 |
2013-11-28 |
University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
CN101578297A
(zh)
|
2006-04-07 |
2009-11-11 |
美国政府健康及人类服务部 |
治疗肿瘤疾病的抗体组合物和方法
|
|
WO2008019290A2
(en)
|
2006-08-04 |
2008-02-14 |
Astrazeneca Ab |
Human antibodies to erbb 2
|
|
BRPI0716438B1
(pt)
|
2006-09-08 |
2022-01-25 |
Abbvie Bahamas Ltd |
Proteínas de ligação a il-13, anticorpo anti-il-13 recombinante, construto de anticorpo, composições farmacêuticas e usos dos mesmos para reduzir a atividade e função biológica da il-13 e tratar distúrbios respiratórios
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
WO2008112193A1
(en)
|
2007-03-12 |
2008-09-18 |
Dana-Farber Cancer Institute |
Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
|
|
PE20081899A1
(es)
|
2007-04-02 |
2009-01-26 |
Pfizer |
Anticuerpos anti-ige
|
|
AU2008275589B2
(en)
|
2007-07-12 |
2013-11-21 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
US20090136465A1
(en)
|
2007-09-28 |
2009-05-28 |
Intrexon Corporation |
Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
|
|
PT2612868T
(pt)
|
2007-11-01 |
2018-10-24 |
Astellas Pharma Inc |
Ácidos nucleicos e polipéptidos imunosupressores
|
|
RU2010129045A
(ru)
|
2007-12-14 |
2012-01-20 |
Бристоль-Мейерз Сквибб Компани (US) |
Связывающие молекулы к рецептору ох40 человека
|
|
KR20100100949A
(ko)
|
2008-01-08 |
2010-09-15 |
브리스톨-마이어스 스큅 컴퍼니 |
증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
|
|
US8263073B2
(en)
|
2008-02-04 |
2012-09-11 |
Medarex, Inc. |
Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
NZ588554A
(en)
|
2008-04-29 |
2013-03-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2009136382A2
(en)
|
2008-05-09 |
2009-11-12 |
Abbott Gmbh & Co. Kg |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2729949A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
|
KR20110040886A
(ko)
|
2008-07-08 |
2011-04-20 |
아보트 러보러터리즈 |
프로스타글란딘 ｅ2 결합 단백질 및 이의 용도
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
BRPI0916973A2
(pt)
|
2008-08-18 |
2016-07-26 |
Amgen Fremont Inc |
anticorpos para ccr2
|
|
KR101012267B1
(ko)
*
|
2008-08-29 |
2011-02-08 |
주식회사 세이프로드 |
파손이 방지되는 차선규제봉 및 차선규제봉 시공방법
|
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
|
ES2568509T3
(es)
|
2009-01-15 |
2016-04-29 |
Adaptive Biotechnologies Corporation |
Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
|
|
CA2752648A1
(en)
|
2009-03-05 |
2010-09-10 |
Abbott Laboratories |
Il-17 binding proteins
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
MX2012000851A
(es)
|
2009-07-20 |
2012-06-08 |
Squibb Bristol Myers Co |
Combinacion de anticuerpo de anti-antigeno 4 asociado al linfocito t citotoxico con diversos regimenes terapeuticos para tratamiento sinergistico de enfermedades proliferativas.
|
|
MX336152B
(es)
|
2009-08-29 |
2016-01-08 |
Abbvie Inc |
Proteinas terapeutico de union a dll4.
|
|
UY32870A
(es)
|
2009-09-01 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
AU2010308030B2
(en)
|
2009-10-12 |
2014-05-29 |
Pfizer Inc. |
Cancer treatment
|
|
CA2775959A1
(en)
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
AU2010329955A1
(en)
|
2009-12-08 |
2012-05-24 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
RU2016146198A
(ru)
|
2010-03-02 |
2018-12-19 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
|
MX360403B
(es)
|
2010-04-15 |
2018-10-31 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
|
LT2571532T
(lt)
|
2010-05-14 |
2017-08-10 |
Abbvie Inc. |
Il-1 surišantys baltymai
|
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2603524A1
(en)
|
2010-08-14 |
2013-06-19 |
AbbVie Inc. |
Amyloid-beta binding proteins
|
|
JP6121903B2
(ja)
|
2010-08-19 |
2017-04-26 |
ゾエティス・ベルジャム・エス・アー |
抗ｎｇｆ抗体およびその使用
|
|
PH12013500337A1
(en)
|
2010-08-26 |
2017-08-23 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
US9221885B2
(en)
*
|
2010-12-02 |
2015-12-29 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for CTLA-4
|
|
AU2011341744B2
(en)
|
2010-12-14 |
2016-09-08 |
Dso National Laboratories |
Human monoclonal antibody with specificity for dengue virus serotype 1 E protein and uses thereof
|
|
SG10201604699VA
(en)
|
2010-12-21 |
2016-07-28 |
Abbvie Inc |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
|
GB201103955D0
(en)
*
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
EP4011913A1
(en)
|
2011-06-30 |
2022-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
|
WO2013013029A1
(en)
|
2011-07-19 |
2013-01-24 |
The Board Of Trustees Of The University Of Illinois |
Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
|
|
MX359314B
(es)
|
2011-08-30 |
2018-09-25 |
Astex Pharmaceuticals Inc Star |
Formulaciones derivadas de decitabina.
|
|
HK1200322A1
(en)
|
2011-10-24 |
2015-08-07 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
|
CA2853357A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against tnf
|
|
EP2776467A1
(en)
|
2011-11-08 |
2014-09-17 |
Pfizer Inc |
Methods of treating inflammatory disorders using anti-m-csf antibodies
|
|
EP3800200A1
(en)
|
2011-12-14 |
2021-04-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
JP6336397B2
(ja)
|
2011-12-14 |
2018-06-06 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
鉄関連障害を診断および治療するための組成物および方法
|
|
CN104159920A
(zh)
|
2011-12-30 |
2014-11-19 |
艾伯维公司 |
针对il-13和/或il-17的双重可变结构域免疫球蛋白
|
|
BR112014018592B1
(pt)
|
2012-01-27 |
2022-03-15 |
Abbvie Inc. |
Anticorpo monoclonal isolado que se liga à molécula de orientação repulsiva a (rgma)
|
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
|
WO2013155447A1
(en)
|
2012-04-13 |
2013-10-17 |
Children's Medical Center Corporation |
Tiki inhibitors
|
|
PL2844282T3
(pl)
|
2012-05-04 |
2019-11-29 |
Pfizer |
Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
|
|
US20150118244A1
(en)
|
2012-05-10 |
2015-04-30 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
ES2894852T3
(es)
|
2012-06-06 |
2022-02-16 |
Zoetis Services Llc |
Anticuerpos anti-NGF caninizados y métodos de los mismos
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
|
PL2887959T3
(pl)
*
|
2012-08-23 |
2019-04-30 |
Agensys Inc |
Koniugaty leków i przeciwciał (adc), które wiążą białka 158p1d7
|
|
KR20180008921A
(ko)
|
2012-11-01 |
2018-01-24 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
|
EP2961388B1
(en)
|
2013-03-01 |
2019-04-24 |
Astex Pharmaceuticals, Inc. |
Drug combinations
|
|
EP2968526A4
(en)
|
2013-03-14 |
2016-11-09 |
Abbott Lab |
HCV ANTIGEN ANTIBODY COMBINATION TEST AND METHOD AND COMPOSITIONS FOR USE THEREOF
|
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
|
EP3916103A1
(en)
|
2013-03-14 |
2021-12-01 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
|
CN105452292A
(zh)
|
2013-03-14 |
2016-03-30 |
帕卡什·吉尔 |
使用结合细胞表面grp78的抗体进行癌症治疗
|
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
US10183988B2
(en)
|
2013-06-07 |
2019-01-22 |
Duke University |
Anti-Complement factor H antibodies
|
|
PT3030262T
(pt)
|
2013-08-08 |
2019-12-11 |
Inst Gustave Roussy Igr |
Composição farmacêutica de associação
|
|
AU2014304931B2
(en)
|
2013-08-08 |
2018-05-10 |
Assistance Publique - Hopitaux De Paris |
IL-15 and IL-15Raplha sushi domain based modulokines
|
|
KR20160055269A
(ko)
|
2013-09-20 |
2016-05-17 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
|
|
TR201903074T4
(tr)
|
2013-11-01 |
2019-03-21 |
Pfizer |
Prostat ile bağlantılı antijenlerin ekspresyonuna yönelik vektörler.
|
|
BR112016010224A2
(pt)
|
2013-11-05 |
2018-05-02 |
Cognate Bioservices, Inc. |
combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
|
|
WO2015069703A1
(en)
|
2013-11-06 |
2015-05-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
EP3094650A2
(en)
|
2014-01-13 |
2016-11-23 |
Pieris Pharmaceuticals GmbH |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
PL3148579T3
(pl)
|
2014-05-28 |
2021-07-19 |
Agenus Inc. |
Przeciwciała anty-gitr i sposoby ich zastosowania
|
|
HRP20192098T1
(hr)
|
2014-06-06 |
2020-02-21 |
Bristol-Myers Squibb Company |
Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
|
JP6214790B2
(ja)
|
2014-09-16 |
2017-10-18 |
イース チャーム リミテッド |
抗ｅｇｆｒ抗体および同抗体の使用法
|
|
AU2015330731B2
(en)
|
2014-10-10 |
2020-07-09 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using TLR9 agonist with checkpoint inhibitors
|
|
WO2016061286A2
(en)
|
2014-10-14 |
2016-04-21 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
WO2016070769A1
(zh)
*
|
2014-11-04 |
2016-05-12 |
北京韩美药品有限公司 |
同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
|
|
WO2016074580A1
(zh)
*
|
2014-11-14 |
2016-05-19 |
中国科学院上海生命科学研究院 |
一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
|
|
CA2968382A1
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
SMT202000413T1
(it)
|
2014-11-21 |
2020-09-10 |
Bristol Myers Squibb Co |
Anticorpi nei confronti di cd73 e loro usi
|
|
US20170355768A1
(en)
|
2014-12-04 |
2017-12-14 |
Bristol-Myers Squibb Company |
Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
|
|
CN104387453A
(zh)
*
|
2014-12-08 |
2015-03-04 |
深圳市同康生物医药有限公司 |
树突状细胞靶向肽及编码基因及应用
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
CN110256558B
(zh)
|
2014-12-23 |
2023-07-04 |
百时美施贵宝公司 |
针对tigit的抗体
|
|
JP6885867B2
(ja)
|
2014-12-31 |
2021-06-16 |
チェックメイト ファーマシューティカルズ， インコーポレイテッド |
組合せ腫瘍免疫療法
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
AU2016219170B2
(en)
*
|
2015-02-13 |
2021-09-09 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CTLA4
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
CA2981068C
(en)
|
2015-03-26 |
2021-12-14 |
Women & Infants Hospital Of Rhode Island |
Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
|
|
CN107530432B
(zh)
|
2015-04-07 |
2021-04-27 |
Cytlimic公司 |
药物
|
|
ES2905525T3
(es)
|
2015-05-06 |
2022-04-11 |
Snipr Tech Ltd |
Alteración de poblaciones microbianas y modificación de la microbiota
|
|
HK1251174A1
(zh)
|
2015-05-22 |
2019-01-25 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
|
CR20170592A
(es)
|
2015-05-29 |
2018-02-13 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos
|
|
CN108137687B
(zh)
|
2015-05-29 |
2021-10-29 |
百时美施贵宝公司 |
抗ox40抗体及其用途
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
US10925867B2
(en)
|
2015-06-29 |
2021-02-23 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer
|
|
UY36757A
(es)
|
2015-06-29 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
|
|
AU2016287585B2
(en)
|
2015-07-02 |
2020-12-17 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
|
KR20210089270A
(ko)
|
2015-07-16 |
2021-07-15 |
바이오카인 테라퓨틱스 리미티드 |
암 치료용 조성물 및 방법
|
|
CA2991628C
(en)
|
2015-07-16 |
2020-04-07 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
|
WO2017021913A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
AU2016319133B2
(en)
|
2015-09-11 |
2023-06-08 |
Mark C. Glassy |
Enhanced delivery of drugs to the brain
|
|
US11594135B2
(en)
|
2015-11-02 |
2023-02-28 |
Memgen, Inc. |
Methods of CD40 activation and immune checkpoint blockade
|
|
WO2017079215A1
(en)
|
2015-11-03 |
2017-05-11 |
Glycomimetics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
|
EP3371221A2
(en)
|
2015-11-07 |
2018-09-12 |
MultiVir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
KR20180082563A
(ko)
|
2015-11-19 |
2018-07-18 |
브리스톨-마이어스 스큅 컴퍼니 |
글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
|
|
MX2018006477A
(es)
|
2015-12-02 |
2018-09-03 |
Agenus Inc |
Anticuerpos y metodos de uso de estos.
|
|
BR112018011781A2
(en)
|
2015-12-14 |
2018-12-04 |
Macrogenics, Inc. |
bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
MX2018011204A
(es)
|
2016-03-15 |
2019-03-07 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso.
|
|
AU2017234192B2
(en)
|
2016-03-16 |
2024-04-04 |
Amal Therapeutics Sa |
Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
|
|
CN109195990A
(zh)
|
2016-03-30 |
2019-01-11 |
Musc研究发展基金会 |
通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
KR102414558B1
(ko)
|
2016-04-18 |
2022-06-29 |
셀덱스 쎄라퓨틱스, 인크. |
인간 cd40에 결합하는 효능성 항체 및 이의 용도
|
|
IL262643B2
(en)
|
2016-04-29 |
2023-09-01 |
Univ Texas |
Targeted measurement of hormone receptor-associated transcriptional activity
|
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CN109641044A
(zh)
|
2016-05-30 |
2019-04-16 |
吉奥瓦科斯公司 |
用于产生对乙型肝炎病毒的免疫应答的组合物和方法
|
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
KR102531889B1
(ko)
|
2016-06-20 |
2023-05-17 |
키맵 리미티드 |
항-pd-l1 및 il-2 사이토카인
|
|
CN109983121A
(zh)
|
2016-06-30 |
2019-07-05 |
昂克诺斯公司 |
治疗性多肽的假型化溶瘤病毒递送
|
|
CN117683135A
(zh)
|
2016-07-14 |
2024-03-12 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
JP7346291B2
(ja)
|
2016-09-21 |
2023-09-19 |
アマル セラピューティクス エスエー |
癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
|
|
KR102530297B1
(ko)
|
2016-09-27 |
2023-05-10 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
|
|
CA3036714A1
(en)
|
2016-10-03 |
2018-04-12 |
Abbott Laboratories |
Improved methods of assessing uch-l1 status in patient samples
|
|
JP6976322B2
(ja)
*
|
2016-10-10 |
2021-12-08 |
クラウン バイオサイエンス，インコーポレイテッド（タイツァン） |
新規抗ｃｔｌａ４抗体
|
|
RU2759728C2
(ru)
|
2016-10-11 |
2021-11-17 |
Ситлимик Инк. |
Лекарственное средство
|
|
SG11201903283UA
(en)
|
2016-10-12 |
2019-05-30 |
Univ Texas |
Methods and compositions for tusc2 immunotherapy
|
|
EP3532504A1
(en)
|
2016-10-28 |
2019-09-04 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
|
AU2017356860A1
(en)
*
|
2016-11-08 |
2019-05-16 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-PD1 and anti-CTLA4 antibodies
|
|
CA3043356A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
|
|
CA3044432A1
(en)
|
2016-11-17 |
2018-05-24 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
|
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
JP2020511407A
(ja)
|
2016-12-01 |
2020-04-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
CA3045241A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
CA3046961A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
JPWO2018110515A1
(ja)
|
2016-12-12 |
2019-10-24 |
第一三共株式会社 |
抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
US11319372B2
(en)
*
|
2017-02-21 |
2022-05-03 |
Remd Biotherapeutics, Inc. |
Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
|
|
CN110612447B
(zh)
|
2017-02-24 |
2024-02-06 |
德克萨斯州立大学董事会 |
用于检测早期胰腺癌的测定
|
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
|
WO2018160538A1
(en)
|
2017-02-28 |
2018-09-07 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
WO2018167778A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
|
EP3601355A1
(en)
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
CN110546513A
(zh)
|
2017-04-15 |
2019-12-06 |
雅培实验室 |
使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
|
|
US11760777B2
(en)
|
2017-04-26 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
|
JP7080899B2
(ja)
|
2017-04-28 |
2022-06-06 |
アボット・ラボラトリーズ |
同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
NZ758316A
(en)
|
2017-05-19 |
2025-08-29 |
Wuxi Biologics Shanghai Co Ltd |
Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
|
|
CN108948194B
(zh)
*
|
2017-05-19 |
2023-02-17 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
|
AU2018272054B2
(en)
|
2017-05-25 |
2024-10-31 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
|
CN116333129A
(zh)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
|
WO2018222784A1
(en)
|
2017-05-30 |
2018-12-06 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
|
|
JP2020522691A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｌａｇ−３陽性腫瘍の処置
|
|
EP3630842A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
AU2018275209A1
(en)
|
2017-05-30 |
2019-10-17 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
|
|
JP7657023B2
(ja)
|
2017-06-09 |
2025-04-04 |
プロビデンス ヘルス アンド サービシーズ－オレゴン |
がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用
|
|
WO2019010131A1
(en)
|
2017-07-03 |
2019-01-10 |
Abbott Laboratories |
IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
|
|
NZ761519A
(en)
|
2017-07-14 |
2023-07-28 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
JP7160491B2
(ja)
|
2017-07-14 |
2022-10-25 |
ファイザー インコーポレイティッド |
ＭＡｄＣＡＭに対する抗体
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
RU2020108580A
(ru)
|
2017-08-03 |
2021-09-03 |
Оцука Фармасьютикал Ко., Лтд. |
Лекарственное соединение и способы его очистки
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
KR102760684B1
(ko)
|
2017-09-29 |
2025-01-24 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하기 위한 조성물 및 방법
|
|
AU2018345715A1
(en)
|
2017-10-06 |
2020-05-21 |
The Wistar Institute Of Anatomy And Biology |
DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
CA3081336A1
(en)
|
2017-10-12 |
2019-04-18 |
Gregory LIZEE |
T cell receptors for immunotherapy
|
|
JP2020536894A
(ja)
|
2017-10-15 |
2020-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
腫瘍処置法
|
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
AU2018365880A1
(en)
|
2017-11-07 |
2020-05-28 |
The Board Of Regents Of The University Of Texas System |
Targeting LILRB4 with car-T or car-NK cells in the treatment of cancer
|
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN108003238B
(zh)
*
|
2017-11-30 |
2021-02-02 |
常州费洛斯药业科技有限公司 |
一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
|
|
CA3067055A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
|
|
CN111094983A
(zh)
|
2017-12-09 |
2020-05-01 |
雅培实验室 |
使用胶质细胞原纤维酸性蛋白(gfap)和/或泛素羧基末端水解酶l1(uch-l1)帮助诊断和评价已遭受骨科损伤并已遭受或可能已遭受头部损伤诸如轻度创伤性脑损伤(tbi)的患者的方法
|
|
MX2020006585A
(es)
*
|
2017-12-20 |
2020-09-25 |
Harbour Biomed Shanghai Co Ltd |
Anticuerpos que se unen a ctla-4 y usos de los mismos.
|
|
US20220305127A1
(en)
|
2017-12-21 |
2022-09-29 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
EP3732198A1
(en)
|
2017-12-27 |
2020-11-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
US12129297B2
(en)
|
2018-01-12 |
2024-10-29 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
|
CA3088542A1
(en)
|
2018-01-22 |
2019-07-25 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019160866A2
(en)
|
2018-02-13 |
2019-08-22 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
US10982002B2
(en)
|
2018-03-12 |
2021-04-20 |
Zoetis Services Llc |
Anti-NGF antibodies and methods thereof
|
|
SG11202008696RA
(en)
|
2018-03-12 |
2020-10-29 |
Inst Nat Sante Rech Med |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
|
US20230167177A1
(en)
*
|
2018-03-19 |
2023-06-01 |
WuXi Biologics Ireland Limited |
Novel anti-ctla-4 antibody polypeptide
|
|
US12454561B2
(en)
|
2018-03-19 |
2025-10-28 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
KR102874694B1
(ko)
|
2018-03-21 |
2025-10-23 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
AU2019246043B2
(en)
|
2018-03-25 |
2024-07-04 |
Snipr Biome Aps. |
Treating and preventing microbial infections
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
EP3773551B1
(en)
|
2018-03-27 |
2024-10-16 |
Board of Regents, The University of Texas System |
Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
|
|
KR20200139724A
(ko)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
JP7511478B2
(ja)
|
2018-04-09 |
2024-07-05 |
チェックメイト ファーマシューティカルズ |
ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
|
|
SG11202010159RA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
BR112020021539A2
(pt)
|
2018-04-25 |
2021-01-19 |
Innate Tumor Immunity, Inc. |
Moduladores de nlrp3
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
CA3103610A1
(en)
|
2018-06-12 |
2019-12-19 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
MX2021000009A
(es)
|
2018-07-09 |
2021-03-09 |
Five Prime Therapeutics Inc |
Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
|
|
WO2020014543A2
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
PE20210687A1
(es)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
Anticuerpos de union a vista a ph acido
|
|
WO2020018879A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
WO2020037091A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
EP3837015B1
(en)
|
2018-08-16 |
2024-02-14 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
BR112021002642A2
(pt)
|
2018-08-16 |
2021-05-04 |
Innate Tumor Immunity, Inc. |
compostos de 4-amino-1h-imidazo[4,5-c]quinolina substituídos e métodos aprimorados para a preparação dos mesmos
|
|
EP3617230A1
(en)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Novel antibodies and nucleotide sequences, and uses thereof
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
US20220073638A1
(en)
|
2018-09-19 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
WO2020057645A1
(zh)
|
2018-09-21 |
2020-03-26 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
WO2020057646A1
(zh)
|
2018-09-21 |
2020-03-26 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
US20220040183A1
(en)
|
2018-10-01 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
MA53822A
(fr)
|
2018-10-03 |
2021-08-11 |
Xencor Inc |
Protéines de fusion fc hétérodimères d'il -12
|
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
|
MA53862A
(fr)
|
2018-10-12 |
2022-01-19 |
Xencor Inc |
Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
|
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
|
KR20210084546A
(ko)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
|
|
US20210405057A1
(en)
|
2018-11-09 |
2021-12-30 |
Pierian Biosciences, LLC |
Methods and compositions for determining the composition of a tumor microenvironment
|
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
|
EP3883955A1
(en)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
US20220106400A1
(en)
|
2018-11-28 |
2022-04-07 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
EP3887823B1
(en)
|
2018-11-28 |
2024-01-17 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kit for assaying lytic potential of immune effector cells
|
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
JP7535794B2
(ja)
|
2018-11-29 |
2024-08-19 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞のエクスビボ増殖のための方法およびその使用方法
|
|
WO2020115262A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
SG11202104331YA
(en)
|
2018-12-11 |
2021-05-28 |
Theravance Biopharma R&D Ip Llc |
Naphthyridine and quinoline derivatives useful as alk5 inhibitors
|
|
EP3897624A1
(en)
|
2018-12-17 |
2021-10-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of sulconazole as a furin inhibitor
|
|
EP3902833A2
(en)
|
2018-12-26 |
2021-11-03 |
City of Hope |
Activatable masked anti-ctla4 binding proteins
|
|
CN113453712A
(zh)
|
2018-12-28 |
2021-09-28 |
特兰斯吉恩股份有限公司 |
M2缺陷型痘病毒
|
|
KR102815870B1
(ko)
|
2019-01-14 |
2025-05-30 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제
|
|
JP7335341B2
(ja)
|
2019-01-14 |
2023-08-29 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
ES2981835T3
(es)
|
2019-01-14 |
2024-10-10 |
Innate Tumor Immunity Inc |
Quinazolinas sustituidas como moduladores de NLRP3, para su uso en el tratamiento del cáncer
|
|
US12338228B2
(en)
|
2019-01-14 |
2025-06-24 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
JP7645185B2
(ja)
|
2019-01-15 |
2025-03-13 |
アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル |
変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
WO2020182993A1
(en)
|
2019-03-13 |
2020-09-17 |
Etherna Immunotherapies Nv |
Mrna vaccine
|
|
WO2020191084A1
(en)
|
2019-03-18 |
2020-09-24 |
The Regents Of The University Of California |
Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells
|
|
JP2022526960A
(ja)
|
2019-03-28 |
2022-05-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
|
CN113677402A
(zh)
|
2019-03-28 |
2021-11-19 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
US20220177978A1
(en)
|
2019-04-02 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
EP3947640A4
(en)
|
2019-04-02 |
2022-12-14 |
The Brigham & Women's Hospital, Inc. |
PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
EP3956446A1
(en)
|
2019-04-17 |
2022-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
KR20220007879A
(ko)
|
2019-05-09 |
2022-01-19 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
간세포 생성 방법
|
|
TW202110431A
(zh)
|
2019-05-17 |
2021-03-16 |
美商癌症預防製藥股份有限公司 |
治療家族性腺瘤性瘜肉症之方法
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
BR112021024402A2
(pt)
|
2019-06-03 |
2022-02-15 |
Univ Chicago |
Métodos e composições para tratamento de câncer com adjuvantes direcionados ao câncer
|
|
EP3976111A4
(en)
|
2019-06-03 |
2023-07-05 |
The University of Chicago |
Methods and compositions for treating cancer with collagen binding drug carriers
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
AU2020301582A1
(en)
|
2019-06-27 |
2022-02-03 |
Etherna Immunotherapies Nv |
Combination therapy
|
|
WO2021003432A1
(en)
|
2019-07-02 |
2021-01-07 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
BR112022000721A2
(pt)
|
2019-07-15 |
2022-03-08 |
Intervet Int Bv |
Anticorpos caninizados contra ctla-4 canina
|
|
AU2020312687A1
(en)
|
2019-07-15 |
2022-01-27 |
Intervet International B.V. |
Caninized antibodies to human and canine CTLA-4
|
|
WO2021024742A1
(ja)
*
|
2019-08-06 |
2021-02-11 |
国立大学法人筑波大学 |
細胞傷害アッセイ方法
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
JP2022548747A
(ja)
|
2019-09-17 |
2022-11-21 |
バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ |
酸性セラミダーゼ阻害剤としての置換されたｎ－複素環式カルボキサミド及び医薬としてのその使用
|
|
JP2022549227A
(ja)
|
2019-09-17 |
2022-11-24 |
バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ |
医学的障害の治療における使用のための置換された飽和および不飽和ｎ－複素環式カルボキサミドおよび関連化合物
|
|
AU2020349516A1
(en)
|
2019-09-17 |
2022-03-17 |
Bial-R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
|
BR112022004831A2
(pt)
|
2019-09-19 |
2022-06-07 |
Bristol Myers Squibb Co |
Anticorpos que se ligam a vista em ph ácido
|
|
KR20220066334A
(ko)
|
2019-09-22 |
2022-05-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
|
|
CA3151747A1
(en)
|
2019-09-23 |
2021-04-01 |
James J. MOON |
Compositions and methods for increasing the efficacy of immunotherapies and vaccines
|
|
US20210115127A1
(en)
|
2019-09-25 |
2021-04-22 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
CA3157024A1
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
EP4049675A4
(en)
|
2019-10-25 |
2023-11-22 |
Daiichi Sankyo Company, Limited |
Combination of anti-garp antibody and immunoregulator
|
|
WO2021087458A2
(en)
|
2019-11-02 |
2021-05-06 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092380A1
(en)
|
2019-11-08 |
2021-05-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
AU2020385400A1
(en)
|
2019-11-22 |
2022-06-09 |
Theravance Biopharma R&D Ip, Llc |
Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
|
|
TW202128155A
(zh)
|
2019-11-27 |
2021-08-01 |
日商賽多利克公司 |
醫藥組成物
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
US20230089255A1
(en)
|
2019-12-19 |
2023-03-23 |
Bristol-Myers Squibb Company |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
IL294226B2
(en)
|
2019-12-27 |
2025-05-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies and their use
|
|
IL294557A
(en)
|
2020-01-07 |
2022-09-01 |
Univ Texas |
Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
CN115244052A
(zh)
|
2020-01-10 |
2022-10-25 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
AU2021215936A1
(en)
|
2020-02-05 |
2022-08-25 |
Larimar Therapeutics, Inc. |
TAT peptide binding proteins and uses thereof
|
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
EP4110810A1
(en)
|
2020-02-28 |
2023-01-04 |
Orega Biotech |
Combination therapies based on ctla4 and il-17b inhibitors
|
|
KR20220150353A
(ko)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
|
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル－マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するｃｄ４０に対する抗体
|
|
CA3172449A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
EP4126824A1
(en)
|
2020-03-31 |
2023-02-08 |
Theravance Biopharma R&D IP, LLC |
Substituted pyrimidines and methods of use
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
|
CA3175499A1
(en)
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
|
US12159700B2
(en)
|
2020-04-22 |
2024-12-03 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
JP2023528223A
(ja)
|
2020-05-13 |
2023-07-04 |
ディスク・メディシン・インコーポレイテッド |
骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
|
|
CA3177717A1
(en)
|
2020-05-13 |
2021-11-18 |
Adagene Ag |
Compositions and methods for treating cancer
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
JP2023526416A
(ja)
|
2020-05-21 |
2023-06-21 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｖｇｌｌ１特異性を有するｔ細胞受容体およびその使用法
|
|
CN115803062B
(zh)
|
2020-06-03 |
2025-09-09 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
US20230279116A1
(en)
|
2020-06-03 |
2023-09-07 |
Mv Biotherapeutics Sa |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
|
US20210387983A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Crystalline alk5 inhibitors and uses thereof
|
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
KR20230152783A
(ko)
|
2020-07-07 |
2023-11-03 |
칸큐어 엘엘씨 |
Mic 항체 및 결합제 및 이의 사용 방법
|
|
US20250262293A1
(en)
|
2020-07-07 |
2025-08-21 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
|
MX2023001055A
(es)
|
2020-07-24 |
2023-03-17 |
Amgen Inc |
Inmunógenos derivados de la proteína de la espícula del sars-cov2.
|
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
|
CN112359052B
(zh)
*
|
2020-08-20 |
2023-01-03 |
山东兴瑞生物科技有限公司 |
抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
|
|
KR20230058442A
(ko)
|
2020-08-28 |
2023-05-03 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 lag-3 길항제 요법
|
|
CN116438199A
(zh)
|
2020-08-31 |
2023-07-14 |
百时美施贵宝公司 |
细胞定位特征和免疫疗法
|
|
WO2022087402A1
(en)
|
2020-10-23 |
2022-04-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
US20240009241A1
(en)
|
2020-11-05 |
2024-01-11 |
Board Of Regents, The University Of Texas System |
Engineered t cell receptors targeting egfr antigens and methods of use
|
|
EP4243839A1
(en)
|
2020-11-13 |
2023-09-20 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
EP4251645A1
(en)
|
2020-11-25 |
2023-10-04 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
JP2024500093A
(ja)
*
|
2020-12-10 |
2024-01-04 |
ウーシー バイオロジクス アイルランド リミテッド |
Ｐ－カドヘリンに対する抗体及びその使用
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
WO2022136650A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Murine cross-reactive human ccr8 binders
|
|
EP4267617A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Human ccr8 binders
|
|
EP4267618A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Non-blocking human ccr8 binders
|
|
EP4267105B1
(en)
|
2020-12-28 |
2025-03-26 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
|
EP4281116A1
(en)
|
2021-01-19 |
2023-11-29 |
William Marsh Rice University |
Bone-specific delivery of polypeptides
|
|
KR20230135075A
(ko)
|
2021-01-22 |
2023-09-22 |
멘두스 비.브이. |
종양 백신접종 방법
|
|
EP4284950A4
(en)
|
2021-01-29 |
2024-12-25 |
Board of Regents, The University of Texas System |
METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS
|
|
WO2022190058A1
(en)
|
2021-03-12 |
2022-09-15 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
AU2022253474A1
(en)
|
2021-04-08 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
|
JP7717832B2
(ja)
|
2021-04-10 |
2025-08-04 |
ジェンマブ エー／エス |
Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
|
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
|
WO2022223622A1
(en)
|
2021-04-20 |
2022-10-27 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
EP4079311B1
(en)
|
2021-04-20 |
2025-10-01 |
Nuvamid SA |
Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
|
US20250066490A1
(en)
|
2021-04-23 |
2025-02-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
EP4341699A1
(en)
|
2021-05-18 |
2024-03-27 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
KR20240049794A
(ko)
|
2021-06-07 |
2024-04-17 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
|
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
|
TWI879694B
(zh)
|
2021-06-25 |
2025-04-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
CR20240026A
(es)
|
2021-06-25 |
2024-03-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
US20240316005A1
(en)
|
2021-07-05 |
2024-09-26 |
Institut National de la Santé et de la Recherche Médicale |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
US20240327544A1
(en)
|
2021-07-13 |
2024-10-03 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
JP2024531910A
(ja)
|
2021-08-04 |
2024-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト |
Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
|
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
EP4396587A1
(en)
|
2021-08-31 |
2024-07-10 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
|
CN118715440A
(zh)
|
2021-08-31 |
2024-09-27 |
雅培实验室 |
诊断脑损伤的方法和系统
|
|
JP2024538608A
(ja)
|
2021-09-30 |
2024-10-23 |
アボット・ラボラトリーズ |
脳の損傷を診断する方法及びシステム
|
|
JP2024537176A
(ja)
|
2021-10-05 |
2024-10-10 |
サイトヴィア セラピューティクス， エルエルシー |
ナチュラルキラー細胞及びその使用方法
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
MX2024004365A
(es)
|
2021-10-20 |
2024-04-25 |
Takeda Pharmaceuticals Co |
Composiciones que actuan sobre el antigeno de maduracion de linfocitos b (bcma) y metodos de uso de las mismas.
|
|
US20240409934A1
(en)
|
2021-10-25 |
2024-12-12 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
CN118176214A
(zh)
|
2021-10-29 |
2024-06-11 |
百时美施贵宝公司 |
血液癌症的lag-3拮抗剂疗法
|
|
US20250090680A1
(en)
|
2021-11-19 |
2025-03-20 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
EP4436998A1
(en)
*
|
2021-11-24 |
2024-10-02 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
|
AU2022413677A1
(en)
|
2021-12-17 |
2024-06-27 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
|
TW202332687A
(zh)
|
2021-12-23 |
2023-08-16 |
比利時商ｅＴｈｅＲＮＡ免疫治療公司 |
免疫刺激性mrna組成物及其用途
|
|
CN118765285A
(zh)
|
2022-01-26 |
2024-10-11 |
百时美施贵宝公司 |
用于肝细胞癌的组合疗法
|
|
JP2025507303A
(ja)
|
2022-02-04 |
2025-03-18 |
アボット・ラボラトリーズ |
試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
|
|
US20250179174A1
(en)
|
2022-02-25 |
2025-06-05 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
JP2025509832A
(ja)
|
2022-03-15 |
2025-04-11 |
コンピュジェン リミテッド |
Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
|
|
CN119031932A
(zh)
|
2022-03-16 |
2024-11-26 |
第一三共株式会社 |
多特异性分子和免疫检查点抑制剂的组合
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
JP2025517908A
(ja)
|
2022-05-24 |
2025-06-12 |
第一三共株式会社 |
抗ｃｄｈ６抗体－薬物コンジュゲートの投薬量レジメン
|
|
EP4531916A1
(en)
|
2022-06-02 |
2025-04-09 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
CN120167040A
(zh)
|
2022-06-29 |
2025-06-17 |
雅培实验室 |
用于确定生物样本中的gfap的磁性定点照护型系统和测定
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
AU2023300419A1
(en)
|
2022-07-01 |
2025-01-02 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
US20250360222A1
(en)
|
2022-07-28 |
2025-11-27 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
JP2025532597A
(ja)
|
2022-09-15 |
2025-10-01 |
アボット・ラボラトリーズ |
軽度及び超軽度の外傷性脳損傷を区別するためのバイオマーカー及び方法
|
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
AU2023393653A1
(en)
|
2022-12-14 |
2025-05-22 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
IL321575A
(en)
|
2022-12-21 |
2025-08-01 |
Bristol Myers Squibb Co |
Combination therapy for lung cancer
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024211475A1
(en)
|
2023-04-04 |
2024-10-10 |
Abbott Laboratories |
Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
WO2024226969A1
(en)
|
2023-04-28 |
2024-10-31 |
Abbott Point Of Care Inc. |
Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
EP4484445A1
(en)
|
2023-06-26 |
2025-01-01 |
Universität zu Köln |
Hcmv neutralizing antibodies
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
EP4590715A1
(en)
|
2023-09-21 |
2025-07-30 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
|
WO2025061993A1
(en)
|
2023-09-21 |
2025-03-27 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025133175A1
(en)
|
2023-12-21 |
2025-06-26 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
EP4574165A1
(en)
|
2023-12-21 |
2025-06-25 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
US20250269052A1
(en)
|
2024-02-27 |
2025-08-28 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025202222A1
(en)
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|
|
WO2025210175A1
(en)
|
2024-04-04 |
2025-10-09 |
Centre National De La Recherche Scientifique |
Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|